DOI QR코드

DOI QR Code

Perfusion Computed Tomography in Predicting Treatment Response of Advanced Esophageal Squamous Cell Carcinomas

  • Li, Ming-Huan (Department of Radiation Oncology, Shandong Cancer Hospital and Institute) ;
  • Shang, Dong-Ping (Department of Radiology, Shandong Cancer Hospital and Institute) ;
  • Chen, Chen (Department of Radiation Oncology, Shandong Cancer Hospital and Institute) ;
  • Xu, Liang (Department of Radiology, Shandong Cancer Hospital and Institute) ;
  • Huang, Yong (Department of Radiology, Shandong Cancer Hospital and Institute) ;
  • Kong, Li (Department of Radiation Oncology, Shandong Cancer Hospital and Institute) ;
  • Yu, Jin-Ming (Department of Radiation Oncology, Shandong Cancer Hospital and Institute)
  • 발행 : 2015.02.25

초록

Background: The purpose of this study was to prospectively evaluate the predictive value of perfusion computed tomography (CT) for response of local advanced esophageal carcinoma to radiotherapy and chemotherapy. Materials and Methods: Before any treatment, forty-three local advanced esophageal squamous cell carcinomas were prospectively evaluated by perfusion scan with 16-row CT from June 2009 to January 2012. Perfusion parameters, including perfusion (BF), peak enhanced density (PED), blood volume (BV), and time to peak (TTP) were measured using Philips perfusion software. Seventeen cases received definitive radiotherapy and 26 received concurrent chemo-radiotherapy. The response was evaluated by CT scan and esophagography. Differences in perfusion parameters between responders and non-responders were analyzed, and ROCs were used to assess predictive value of the baseline parameters for treatment response. Results: There were 25 responders (R) and 18 non-responders (NR). Responders showed significantly higher BF (R:34.1 ml/100g/min vs NR: 25.0 ml/100g/min, p=0.001), BV (23.2 ml/100g vs 18.3 ml/100g, p=0.009) and PED (32.5 HU vs 28.32HU, P=0.003) than non-responders. But the baseline TTP (R: 38.2s vs NR: 44.10s, p=0.172) had no difference in the two groups. For baseline BF, a threshold of 36.1 ml/100g/min achieved a sensitivity of 56%, and a specificity of 94.4% for detection of clinical responders from non-responders. Conclusions: The results suggest that the perfusion CT can provide some helpful information for identifying tumors that may respond to radio-chemotherapy.

키워드

참고문헌

  1. Bedenne L, Michel P, Bouche O, et al (2007). Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol, 25, 1160-8. https://doi.org/10.1200/JCO.2005.04.7118
  2. Bellomi M, Petralia G, Sonzogni A, et al (2007). Perfusion CT for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma:initial experience. Radiology, 244, 486-93. https://doi.org/10.1148/radiol.2442061189
  3. Bisdas S, Rumboldt Z, Surlan-Popovic K, et al (2010). Perfusion CT in squamous cell carcinoma of the upper aerodigestive tract:long-term predictive value of baseline perfusion CT measurements. AJNR Am J Neuroradiol, 31, 576-81. https://doi.org/10.3174/ajnr.A1852
  4. Chen TW, Yang ZG, Wang QL, et al (2011). Whole tumour quantitative measurement of first-pass perfusion of oesophageal squamous cell carcinoma using 64-row multidetector computed tomography:correlation with microvessel density. Eur J Radiol, 79, 218-23. https://doi.org/10.1016/j.ejrad.2010.03.024
  5. Djuric-Stefanovic A, Saranovic Dj, et al (2013). Comparison between the deconvolution and maximum slope 64-MDPerfusion CT analysis of the esophageal cancer: is conversion possible? Eur J Radiol, 82, 1716-23. https://doi.org/10.1016/j.ejrad.2013.05.038
  6. Fournier LS, Oudard S, Thiam R, et al (2010). Metastatic renal carcinoma: evaluation of anti-angiogenic therapy with dynamic contrast enhanced CT. Radiol, 256, 511-8. https://doi.org/10.1148/radiol.10091362
  7. Goh V, Padhani AR (2006). Imaging tumor angiogenesis: functional assessment using MDCT or MRI? Abdom Imaging, 31, 194-9. https://doi.org/10.1007/s00261-005-0387-4
  8. Han KS, Jung DC, Choi HJ, et al (2010). Pretreatment assessment of tumor enhancement on contrastenhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy. Cancer, 116, 2332-42
  9. Hayano K, Okazumi S, Shuto K, et al (2007). Perfusion CT can predict the response to chemoradiation therapy and survival in esophageal squamous cell carcinoma: initial clinical results. Oncol Rep, 18, 901-8.
  10. Kelsen DP, Winter KA, Gunderson LL, et al (2007). Longterm results of RTOG trial 8911 (USA Intergroup 113): a randomassignment trial comparison of chemotherapy followed by surgery compared withsurgery alone for esophageal cancer. J Clin Oncol, 25, 3719-25. https://doi.org/10.1200/JCO.2006.10.4760
  11. Kersting S, Konopke R, Dittert D, et al (2009). Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma? J Gastroenterol Hepatol, 24, 886-95. https://doi.org/10.1111/j.1440-1746.2008.05732.x
  12. Laking GR, West C, Buckley DL, et al (2006). Imaging vascular physiology to monitor cancer treatment. Crit Rev Oncol Hematol, 58, 95-113 https://doi.org/10.1016/j.critrevonc.2005.10.006
  13. Li Y, Yang ZG, Chen TW, et al (2009). Quantitative assessment of first-pass perfusion of oesophageal squamous cell carcinoma using 64-section MDCT: initial observation. Clin Radiol, 64, 38-45. https://doi.org/10.1016/j.crad.2008.06.005
  14. Makari Y, Yasuda T, Doki Y, et al (2007). Correlation between tumor blood flow assessed by perfusion CT and effect of neoadjuvant therapy in advanced esophageal cancers. J Surg Oncol, 96, 220-9. https://doi.org/10.1002/jso.20820
  15. Miyata H, Yamasaki M, Takahashi T, et al (2014). Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET). Ann Surg Oncol, 21, 575-82.
  16. Moulder JE and Rockwell S (1987). Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev, 5, 313-41. https://doi.org/10.1007/BF00055376
  17. Piessen G, Briez N, Triboulet JP, et al (2007). Patients with locally advanced esophageal carcinoma nonresponder to radiochemotherapy: who will benefit from surgery? Ann Surg Oncol, 14, 2036-44. https://doi.org/10.1245/s10434-007-9405-9
  18. Stahl M, Wilke H, Stuschke M, et al (2005). Clinical response to induction chemotherapy predicts local control and longterm survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Onco, 131, 67-72. https://doi.org/10.1007/s00432-004-0604-5
  19. Tsai AG, Johnson PC and Intaglietta M (2003). Oxygen gradients in the microcirculation. Physiol Rev, 83, 933-63. https://doi.org/10.1152/physrev.00034.2002
  20. van Hagen P, Hulshof MC, van Lanschot JJ, et al (2012). Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med, 366, 2074-84. https://doi.org/10.1056/NEJMoa1112088
  21. Wang DB, Zhang X, Han HL, et al (2012). Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: a meta-analysis. Dig Dis Sci, 57, 3226-33. https://doi.org/10.1007/s10620-012-2263-8
  22. Yin LL, Yang ZG, Li Y, et al (2008). (Preliminary study of tumor perfusion assessment with multidetector CT in carcinoma of esophagus and cardia). Sichuan Da Xue Xue Bao Yi Xue Ban, 39, 788-91.
  23. Zhang SC, Hironaka S, Ohtsu A, et al (2006). Computerassisted analysis of biopsy specimen microvessels predicts the outcome of esophageal cancers treated with chemoradiotherapy. Clin Cancer Res, 12, 1735-42. https://doi.org/10.1158/1078-0432.CCR-05-1982
  24. Zhu W, Xing L, Yue J, et al (2012). Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation:a systematic review and meta-analysis. Br J Radiol, 85, 694-701. https://doi.org/10.1259/bjr/29946900
  25. Zima A, Carlos R, Gandhi D, et al (2007). Can pretreatment CT perfusion predict response of advanced squamous cell carcinoma of the upper aerodigestive tract treated with induction chemotherapy? AJNR Am J Neuroradiol, 28, 328-34.